DOCSLIB.ORG

Serotonin Syndrome Learning Objectives • Discuss the Pathophysiology of Serotonin Syndrome (SS)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Serotonin Syndrome Learning Objectives • Discuss the Pathophysiology of Serotonin Syndrome (SS) 9/28/16 Serotonin Syndrome Learning Objectives • Discuss the pathophysiology of serotonin syndrome (SS) Ma# Neukirch Pharm.D., BCPS • Discuss the medicaons and interacIons that may cause SS Iowa Physician Assistant Society • Discuss the diagnosis of SS Fall CME 2016 • Discuss the differenIal diagnosis Coralville, IA • Discuss the management of SS Serotonin syndrome is What is serotonin? • A potenIally life-threatening condiIon • Caused by serotonin toxicity in the central nervous system (CNS) • Serotonin toxicity is a term used to describe the expected and problemac effects of excess serotonergic acIvity • Most oOen results from an overdose or when a • Monoamine neurotransmiPer combinaon of medicaons increase serotonin acIvity • Metabolized by the monoamine oxidase enzyme • It can occur with a single therapeuIc dose of one • Also known as 5-hydroxytryptamine (5-HT) medicaon Source: https://images.google.com What does serotonin do? Demographics and Incidence • CNS roles • SS has been documented in every age group • AenIon • Behavior • Poison center and post-markeIng surveillance data report • Thermoregulaon • Tens of thousand of SSRI exposures are reported every year • ~15 % of those cases lead to SS • Peripheral nervous system roles • ~2-12% of severe SS cases lead to death • GastrointesInal moIlity • VasoconstricIon • SuscepIbility to serotonergic excess seems to vary between • Uterine contracIon individuals • BronchoconstricIon • Platelet aggregaon Bronstein AC, Spyker DA, Cantilena LR Jr. et al. 2001 Annual report of the American Association of Poison Control Center’s National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol 2012;50:911. 1 9/28/16 Serotonin syndrome Mental status changes • Classic clinical triad Symptoms may include • Mental status changes • Agitaon • Neuromuscular abnormaliIes • Anxiety • Autonomic hyperacIvity • Disorientaon • Restlessness • Excitement Neuromuscular abnormalities Autonomic Hyperactivity Symptoms may include Symptoms may include • Tremors • Hypertension • Shivering • Clonus • Tachypnea • Voming • Hyperreflexia • Tachycardia • Diarrhea • Muscle rigidity • Hyperthermia • HyperacIve bowel sounds • Bilateral Babinski Signs • Mydriasis • Arrhythmias • Akathisia • Diaphoresis • Dry mucous membranes • Flushed skin What is serotonin syndrome? Diagnosis Serotoninergic excess causes toxicity on a spectrum This is a clinical diagnosis based on • Medicaon history • Physical exam • Neurological exam • Timing of symptoms Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112. 2 9/28/16 Medication History Causative Medications • Should include all medicaons and recent changes • Medicaons with the following serotonergic effects • PrescripIon meds • Impairs reuptake from the synapIc cleO • Illicit drugs • Direct serotonin receptor agonism • Over-the-counters • Inhibit serotonin metabolism • Alternave medicaons/herbals • Increase release of serotonin • Dietary supplements • Increase sensiIvity of serotonin receptor • Increase serotonin synthesis • Dose or dosing interval changes • Medicaon combinaons can increase serotonin acIvity by • AddiIve effects • Formulaon changes • Altering the metabolism of serotonergic drugs • Immediate release, extended release, etc Meds that impair reuptake from the Meds that impair reuptake from the synaptic cleft synaptic cleft • SelecIve serotonin reuptake inhibitors (SSRIs) • Citalopram, escitalopram, fluoxeIne, fluvoxamine, paroxeIne, • Tricyclic anIdepressants (TCAs) and sertraline • Amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maproIline, nortriptyline, protriptyline, trimipramine • Serotonin-norepinephrine reuptake inhibitors (SNRIs) • Desvenlafaxine, duloxene, milnacipran, and venlafaxine • 5-HT3 receptor antagonists • Dolasetron, granisetron, ondansetron, palonosetron • Dopamine-norepinephrine reuptake inhibitors • Bupropion • CerIan opiods • Fentanyl, meperidine, tapentadol, methadone, and tramadol • Serotonin modulators • Nefazodone, trazodone, and vilazodone • Pentazocine Source: UpToDate Robles LA. Serotonin syndrome induced by fentanyl in a child: a case report.Clin Neuropharmacol 2015; 38:206. Source: UpToDate Meds that impair reuptake from the Meds with direct serotonin receptor synaptic cleft agonism • St. John's wort (Hypericum perforatum) • Buspirone • Metoclopramide • Triptans • Valproate • Sumatriptan, rizatriptan, others • Carbamazepine • Ergot derivaves • Sibutramine • Dihydroergotamine, methylergonovine • Dextromethorphan • Fentanyl • Cyclobenzaprine • Lysergic acid diethylamide (LSD) • MDMA (Ecstasy) • Cocaine Source: UpToDate Source: UpToDate 3 9/28/16 Meds that inhibit serotonin metabolism Meds that increase release of serotonin • Monoamine oxidase inhibitors (MAOIs) • Amphetamines • Phenelzine, tranylcypromine, isocarboxazid, moclobemide, • Dextroamphetamine, methamphetamine, and others selegiline, rasagiline, procarbazine, Syrian rue (Peganum • Amphetamine derivaves harmala/harmine) • Fenfluramine, dexfenfluramine, phentermine • Linezolid • Cocaine • Tedizolid • MDMA (Ecstasy) • Methylene blue • Levodopa Source: UpToDate Source: UpToDate Meds that increase sensitivity of Meds that increase serotonin formation serotonin receptor • Lithium • Tryptophan Source: UpToDate Source: UptoDate and Google Images Drug Interactions Cytochrome P450 enzymes • Combining mulIple serotonergic agents increases risk • Substrate – a drug that is metabolized by a parIcular • Be aware of long acIng meds, like fluoxeIne, which may exhibit enzyme serotonergic effects for weeks aer the last dose • Ex) Venlafaxine is substrate of CYP3A4 • Always consider how medicaons may alter the • Inducer – a drug that increases the acIvity of a parIcular metabolism of serotonergic agents enzyme • Most interacIons involve the cytochrome P450 enzyme system • Ex) Carbamazepine is an inducer of CYP1A2, 2C9, and 3A4 • More than 50 different isoforms responsible for the metabolism of many medicaons • Ex: CPY3A4, CPY2C9, CYP2D9 and so forth • Inhibitor – a drug that decreases the acIvity of a parIcular enzyme • Ex) Ciprofloxacin inhibits CPY1A2 4 9/28/16 Physical exam indings Neurological exam indings • Agitaon • Hypertension Neuromuscular findings may be more pronounced in the lower • Akathisia • Hyperthermia extremies • Anxiety • Increased bowel sounds • Diaphoresis • Mydriasis • Bilateral Babinski Signs • Dry mucus membranes • Shivering • Deep tendon hyperreflexia • Flushed skin • Tachycardia • Inducible or spontaneous clonus • Muscle rigidity • Ocular clonus • Tremor Diagnostic criteria Hunter Criteria Must be exposed to a serotonergic agent and have at least one • Two criteria exist for aiding SS diagnosis below • Sternbach’s criteria - older • Spontaneous clonus • 75% sensiIve and 96% specific for diagnosing SS • Inducible clonus with agitaon or diaphoresis • Ocular clonus with agitaon or diaphoresis • Hunter criteria - newer and most commonly used • Tremor and hyperreflexia • 84% sensiCve and 97% specific for diagnosing SS • Hypertonia • Gold standard is the diagnosis by a medical toxicologist • Temperature above 38⁰C with ocular clonus or inducible clonus Dunkley EJ, Isbister GK, Sibbrit, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnosIc decision rules for serotonin toxicity. Dunkley EJ, Isbister GK, Sibbrit, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnosIc decision rules for serotonin toxicity. QJM 2003; 96:635. QJM 2003; 96:635. Differential Diagnosis Differential Diagnosis • NeurolepIc Malignant Syndrome (NMS) • Malignant Hyperthermia • SympathomimeIc toxicity • AnIcholinergic toxicity • EncephaliIs Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112. 5 9/28/16 What is serotonin syndrome? Management Serotoninergic excess causes toxicity on a spectrum • Mild cases to moderate cases • DisconInue serotonergic agents • Provide supporIve cares • Sedaon with benzodiazepines • Treat autonomic instability and abnormal vital signs • Consider giving a serotonin antagonist if abnormaliIes persist • Severe cases – including hyperthermic paents (>41⁰C) • Endotracheal intubaon • Paralysis Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112. Management Management • DisconInue serotonergic agents Sedaon with benzodiazepines to address • Signs and symptoms generally start to resolve within 24 hours for short acIng agents • Agitaon • Some drugs have longer half lives and/or duraon of effect and thus • Tachycardia toxicity may persist for days • Hypertension • Hyperthermia • Provide supporIve cares • Supplemental 02 to keep sats above 94 % • Titrate dose to achieve sedaon and normal vital signs • Crystalloid fluids for volume depleIon • Cardiac monitoring Management Management • Consider giving a serotonin antagonist • Treat autonomic instability and abnormal vital signs • Cyproheptadine is a 5-HT1A and 5-HT2A receptor antagonist • IniIal dose is 12 mg followed by 2 mg Q2H unIl response • Hypertension • OpImal dosing is not established • Use short acIng agents like esmolol or nitroprusside • Available as 4 mg tablets and 2mg/5mL oral syrup • Avoid long acIng agents like propranolol • Tablets can be crushed and given via nasogastric tube • It is not known if cyproheptadine affects paent outcomes • Hypotension – most oOen seen with MAOI induced SS • Use direct acIng agents like norepinephrine, epinephrine, or • Chlorpromazine and olanzapine are not recommended for use a phenylephrine serotonin antagonists • Avoid dopamine • Undesirable side effect profiles 6 9/28/16 Management Thank You • Paents with temperatures greater than 41.1⁰C • Endotracheal intubaon • Sedaon • Paralysis • Reduce temperature with external cooling • Do not use acetaminophen or dantrolene Quesons ? 7 .
Load more

Recommended publications
  • CP.PMN.158 Netupitant and Palonosetron (Akynzeo)
    Clinical Policy: Netupitant and Palonosetron (Akynzeo), Fosnetupitant and Palonosetron (Akynzeo IV) Reference Number: CP.PMN.158 Effective Date: 09.01.06 Last Review Date: 02.21 Coding Implications Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Netupitant/palonosetron (Akynzeo®) and fosnetupitant/palonosetron are fixed combination products of netupitant, a substance P/neurokinin 1 (NK1) receptor antagonist, and palonosetron hydrochloride, a serotonin (5-HT3) receptor antagonist. FDA Approved Indication(s) Akynzeo capsules are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Akynzeo for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Akynzeo is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Prevention of Nausea and Vomiting Associated with Cancer Chemotherapy (must meet all): 1. Prescribed for the prevention of chemotherapy-induced nausea/vomiting; 2. Age ≥ 18 years; 3. If request is for Akynzeo capsules, member is scheduled to receive moderately to highly emetogenic cancer chemotherapy (see Appendix D); 4. If request is for Akynzeo for injection, member is scheduled to receive highly emetogenic cancer chemotherapy (see Appendix D); 5.
    [Show full text]
  • 203050Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203050Orig1s000 LABELING HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------CONTRAINDICATIONS-------------------------------- These highlights do not include all the information needed to use Hypersensitivity to the drug or any of its components (4) PALONOSETRON HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for PALONOSETRON ------------------------WARNINGS AND PRECAUTIONS------------------------- HYDROCHLORIDE INJECTION. • Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other selective 5-HT3 receptor antagonists PALONOSETRON HYDROCHLORIDE injection, for intravenous (5.1) use • Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone Initial U.S. Approval: 2003 but particularly with concomitant use of serotonergic drugs (5.2, 7.1) -------------------------INDICATIONS AND USAGE------------------------ --------------------------------ADVERSE REACTIONS------------------------------- Palonosetron Hydrochloride (HCl) Injection is a serotonin-3 (5-HT3) The most common adverse reactions in chemotherapy-induced nausea and receptor antagonist indicated in adults for: vomiting (≥5%) are headache and constipation (6.1) • Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat The most common adverse reactions in postoperative nausea and vomiting (≥ courses (1.1) 2%) are QT prolongation,
    [Show full text]
  • Haloperidol As Prophylactic Treatment for Postoperative
    Document downloaded from http://http://www.revcolanest.com.co, day 15/02/2013. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. r e v c o l o m b a n e s t e s i o l . 2 0 1 3;4 1(1):34–43 Revista Colombiana de Anestesiología Colombian Journal of Anesthesiology www.revcolanest.com.co Review Haloperidol as prophylactic treatment for postoperative ଝ nausea and vomiting: Systematic literature review ∗ Catalina Chaparro , Diego Moreno, Verónica Ramírez, Angélica Fajardo, David González, Alejandra Sanín, Reinaldo Grueso Anesthesiology Service, Hospital Universitario San Ignacio, Bogotá, Colombia a r t i c l e i n f o a b s t r a c t Article history: Introduction: The effectiveness of haloperidol for the prophylaxis of postoperative nausea Received 3 July 2012 and vomiting (PONV) has been proven in prior trials summarized by Buttner in 2004. New Accepted 24 July 2012 evidence has surfaced since then. Our objective is thus to update the current knowledge on the topic. A systematic review and a meta-analysis were performed, in order to determine the effectiveness and safety of the use of haloperidol as prophylaxis for PONV. Keywords: Methodology: The systematic search, the selection of relevant articles, the extraction of data, Haloperidol the critical analysis of the primary studies, the comparisons and analyses were all based on Vomiting the recommendations of the Cochrane Collaboration and using RevMan5 software. Nausea Results: Ten controlled clinical trials published between 1962 and 2010, that included 2,711 Clinical trials patients, met the selection criteria.
    [Show full text]
  • Safety and Efficacy of a Continuous Infusion, Patient Controlled Anti
    Bone Marrow Transplantation, (1999) 24, 561–566 1999 Stockton Press All rights reserved 0268–3369/99 $15.00 http://www.stockton-press.co.uk/bmt Safety and efficacy of a continuous infusion, patient controlled anti- emetic pump to facilitate outpatient administration of high-dose chemotherapy SP Dix, MK Cord, SJ Howard, JL Coon, RJ Belt and RB Geller Blood and Marrow Transplant Program, Oncology and Hematology Associates and Saint Luke’s Hospital of Kansas City, Kansas City, MO, USA Summary: and colleagues1 described an outpatient BMT care model utilizing intensive clinic support following inpatient admin- We evaluated the combination of diphenhydramine, lor- istration of HDC. This approach facilitated early patient azepam, and dexamethasone delivered as a continuous discharge and significantly decreased the total number of i.v. infusion via an ambulatory infusion pump with days of hospitalization associated with BMT. More patient-activated intermittent dosing (BAD pump) for recently, equipped BMT centers have extended the out- prevention of acute and delayed nausea/vomiting in patient care approach to include administration of HDC in patients receiving high-dose chemotherapy (HDC) for the clinic setting. Success of the total outpatient care peripheral blood progenitor cell (PBPC) mobilization approach is dependent upon the availability of experienced (MOB) or prior to autologous PBPC rescue. The BAD staff and necessary resources as well as implementation of pump was titrated to patient response and tolerance, supportive care strategies designed to minimize morbidity and continued until the patient could tolerate oral anti- in the outpatient setting. emetics. Forty-four patients utilized the BAD pump Despite improvements in supportive care strategies, during 66 chemotherapy courses, 34 (52%) for MOB chemotherapy-induced nausea and vomiting continues to be and 32 (48%) for HDC with autologous PBPC rescue.
    [Show full text]
  • Akynzeo™ (Netupitant and Palonosetron) Capsule/ Antiemetics
    Drug Monograph Drug/Drug Akynzeo™ (netupitant and palonosetron) capsule/ Class: Antiemetics Prepared for: MO HealthNet Prepared by: Xerox Heritage, LLC New Criteria Revision of Existing Criteria Executive Summary The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open Purpose: access basis to prescribers, require a clinical edit or require prior authorization for use. Akynzeo™ is available as a 300 mg/0.5 mg capsule containing 300 mg of netupitant and 0.5 mg of palonosetron respectively. Dosage Forms & Manufacturer: Eisai Inc, Woodcliff Lake, NJ The efficacy of Akynzeo™ for the prevention of acute and delayed nausea and vomiting due to chemotherapy was demonstrated in two phase 3 clinical trials. Complete response rates (ie, no emesis and no rescue medication) for acute, delayed, and overall nausea and vomiting following a single cycle of moderately emetogenic chemotherapy (n=1455) were 88.4%, 76.9%, and 74.3% for Akynzeo™ plus dexamethasone compared Summary of with 85%, 69.5%, and 66.6% for palonosetron plus dexamethasone. In a Findings: second phase 3 study where patients were randomized to receive Akynzeo™ or aprepitant plus palonosetron (with all patients receiving dexamethasone) for repeated cycles of highly or moderately emetogenic chemotherapy (n=412), complete response rates for the overall phase of nausea and vomiting ranged from 81% to 92% for the Akynzeo™ arm and 76% to 88% for the aprepitant/palonosetron arm through 6 cycles of chemotherapy. Status Prior Authorization (PA) Required Open Access Recommendation: Clinical Edit PDL Type of PA Increased Risk of ADE Preferred Agent Criteria: Appropriate Indications Under Solicitation 2015 Xerox Heritage, LLC All Rights Reserved.
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • The Vomiting Center and the Chemoreceptor Trigger Zone
    Pharmacologic Control of Vomiting Todd R. Tams, DVM, Dipl. ACVIM VCA West Los Angeles Animal Hospital Pharmacologic Control of Acute Vomiting Initial nonspecific management of vomiting includes NPO (in minor cases a 6-12 hour period of nothing per os may be all that is required), fluid support, and antiemetics. Initial feeding includes small portions of a low fat, single source protein diet starting 6-12 hours after vomiting has ceased. Drugs used to control vomiting will be discussed here. The most effective antiemetics are those that act at both the vomiting center and the chemoreceptor trigger zone. Vomiting is a protective reflex and when it occurs only occasionally treatment is not generally required. However, patients that continue to vomit should be given antiemetics to help reduce fluid loss, pain and discomfort. For many years I strongly favored chlorpromazine (Thorazine), a phenothiazine drug, as the first choice for pharmacologic control of vomiting in most cases. The HT-3 receptor antagonists ondansetron (Zofran) and dolasetron (Anzemet) have also been highly effective antiemetic drugs for a variety of causes of vomiting. Metoclopramide (Reglan) is a reasonably good central antiemetic drug for dogs but not for cats. Maropitant (Cerenia) is a superior broad spectrum antiemetic drug and is now recognized as an excellent first choice for control of vomiting in dogs. Studies and clinical experience have now also shown maropitant to be an effective and safe antiemetic drug for cats. While it is labeled only for dogs, clinical experience has shown it is safe to use the drug in cats as well. Maropitant is also the first choice for prevention of motion sickness vomiting in both dogs and cats.
    [Show full text]
  • Comparative Study of Palonosetron and Ondansetron in Prevention of Post Operative Nausea and Vomiting After Laparoscopic Gynaecological Surgeries
    Indian Journal of Clinical Anaesthesia 2020;7(1):59–63 Content available at: iponlinejournal.com Indian Journal of Clinical Anaesthesia Journal homepage: www.innovativepublication.com Original Research Article Comparative study of palonosetron and ondansetron in prevention of post operative nausea and vomiting after laparoscopic gynaecological surgeries Ankita Choudhary1,*, Vinod Parashar1 1Dept. of Anaesthesiology, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India ARTICLEINFO ABSTRACT Article history: Introduction: Post operative nausea and vomiting (PONV) is a common complication after general Received 13-04-2019 anaesthesia, specially post laparoscopic surgeries. This study compared efficacy of palonosetron with Accepted 20-11-2019 ondansetron for prevention and management of PONV in patients undergoing laparoscopic gynaecological Available online 28-02-2020 surgeries. Materials and Methods : 100 patients, undergoing laparoscopic gynaecological surgery were randomly divided in 2 groups of 50 each. They received either ondansetron(4mg IV) or palonosetron (0.075mg IV) Keywords: before induction of general anaesthesia. They were monitored post operatively till 72 hours for episodes of Palonosetron nausea, vomiting, overall PONV and adverse effects. Post operative nausea vomiting Result: The incidence of overall PONV was significantly less in patients who received palonosetron as Laparoscopic gynaecological compared those who received ondansetron. Also, ondansetron group demonstrated higher use of rescue surgeries anti-emetic drug as compared with palonosetron group. No significant difference was found in incidence Anti-emetic drugs of adverse effects in both groups. Ondansetron Conclusion: Palonosetron, having longer duration of action, is more effective in treating long term PONV compared to ondansetron in patients undergoing laparoscopic gynaecological surgeries under general anesthesia. © 2020 Published by Innovative Publication.
    [Show full text]
  • Appendix B Supportive Care
    APPENDIX B SUPPORTIVE CARE 1-4 ACUTE EMESIS PROPHYLAXIS o Dolasetron 100 mg and dexamethasone 20 mg given PO 30 minutes before Minimally Emetogenic Regimes (< 10%) chemotherapy • Prophylactic antiemetic therapy generally is not Palonosetron 0.25 mg IV (day 1 only) required. o and dexamethasone 20 mg PO given 30 • If the patient experiences nausea or vomiting, minutes before chemotherapy use prophylactic therapy prior to subsequent Patients who do not respond to a 2-drug treatments. • combination may benefit from the following: One of the following regimens is recommended: A corticosteroid, dopamine antagonist, and Dexamethasone 8 to 20 mg PO, given 30 serotonin antagonist regimen or minutes before chemotherapy Addition of a neurokinin antagonist to their Prochlorperazine 10 mg PO ± previous regimen. diphenhydramine 25 to 50 mg PO if needed, given 30 minutes before chemotherapy Metoclopramide 0.5 to 2 mg/kg PO ± Mildly Emetogenic Regimens (10% to 30%) diphenhydramine 25 to 50 mg PO if needed, • For most patients, prophylactic antiemetic therapy, given 30 minutes before chemotherapy particularly with a serotonin antagonist, generally is Promethazine 25 to 50 mg PO ± not required. diphenhydramine 25 to 50 mg PO if needed, • If needed, one of the following regimens may be given 30 minutes before chemotherapy given 30 minutes prior to therapy: • If patient still experiences significant nausea Dexamethasone 8 to 20 mg PO, given 30 or vomiting, add an agent from a different minutes before chemotherapy pharmacologic category to the previous Prochlorperazine 10 mg orally ± prophylactic antiemetic regimen. diphenhydramine 25 to 50 mg PO if needed, The following regimens are recommended: given 30 minutes before chemotherapy Patients who received a corticosteroid only: Metoclopramide 0.5 to 2 mg/kg PO ± Add a dopamine antagonist.
    [Show full text]
  • Economic Analysis of Palonosetron Versus
    Shimizu et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:31 https://doi.org/10.1186/s40780-018-0128-9 RESEARCHARTICLE Open Access Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial) Hisanori Shimizu1,13* , Kenichi Suzuki2, Takeshi Uchikura1, Daiki Tsuji3, Takeharu Yamanaka4, Hironobu Hashimoto5, Koichi Goto6, Reiko Matsui7, Nobuhiko Seki8, Toshikazu Shimada9, Shunya Ikeda10, Naoki Ikegami11, Toshihiro Hama2, Nobuyuki Yamamoto12 and Tadanori Sasaki1 Abstract Background: We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant and dexamethasone in preventing chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC). Methods: We retrospectively investigated all medicines prescribed for antiemetic purposes within 120 h after the initiation of cisplatin administration during hospitalization. In the TRIPLE study, patients were assigned to treatment with granisetron (GRA) 1 mg (n = 413) or palonosetron (PALO) 0.75 mg (n = 414). The evaluation measure was the cost-effectiveness ratio (CER) assessed as the cost per complete response (CR; no vomiting/ retching and no rescue medication). The analysis was conducted from the public healthcare payer’s perspective. Results: The CR rates were 59.1% in the GRA group and 65.7% in the PALO group (P = 0.0539), and the total frequencies of rescue medication use for these groups were 717 (153/413 patients) and 573 (123/414 patients), respectively.
    [Show full text]
  • ASCO's Antiemetics Drug, Dose, and Schedule Table
    ASCO 2017 Antiemetics Guideline Update: Drug, Dose, Schedule Recommendations for Antiemetic Regimens Antiemetic Dosing by Chemotherapy Risk Category Agent Dose on Day of Chemotherapy Dose(s) on Subsequent Days High Emetic Risk: Cisplatin and other agents Aprepitant 125 mg oral 80 mg oral; days 2 and 3 Fosaprepitant 150 mg IV NK1 Receptor 300 mg netupitant/0.5 mg palonosetron oral in single Antagonist Netupitant-palonosetron capsule (NEPA) Rolapitant 180 mg oral 2 mg oral or 1 mg or 0.01 mg/kg IV or 1 transdermal Granisetron patch or 10 mg subcutaneous 8 mg oral twice daily or 8 mg oral dissolving tablet Ondansetron twice daily or three 8 mg oral soluble films or 8 mg or 5-HT3 Receptor 0.15 mg/kg IV Antagonista Palonosetron 0.50 mg oral or 0.25 mg IV Dolasetron 100 mg oral ONLY Tropisetron 5 mg oral or 5 mg IV Ramosetron 0.3 mg IV if aprepitant is usedb 12 mg oral or IV 8 mg oral or IV once daily on days 2-4 8 mg oral or IV on day 2; 8 mg oral or IV twice if fosaprepitant is usedb 12 mg oral or IV Dexamethasone daily on days 3-4 if netupitant-palonosetron 12 mg oral or IV 8 mg oral or IV once daily on days 2 to 4 is usedb This table is derived from recommendations in the Antiemetics Guideline Update (2017). This table is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician.
    [Show full text]
  • Medication Coverage Policy
    MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 12/14/2016 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 11/07, 11/15 LOB AFFECTED Medi-Cal, SJHA (MONTH/YEAR) OVERVIEW Prescription and OTC antiemetic medications are used to relieve nausea and/or prevent or stop vomiting. Some medications have more evidence of providing benefit in specific patient populations, such as patients taking chemotherapy or undergoing a procedure that requires anesthesia. While there are many available agents to relieve the symptoms of nausea and vomiting, non-pharmacologic recommendations should be incorporated into every patient care plan.1,2,3 The purpose of this coverage policy is to review the coverage criteria of HPSJ’s formulary anti-nausea agents (Table 1). Table 1: Available Anti-Nausea Medications Generic (Brand) Strength & Dosage form Formulary Notes Limits 5-HT3 Antagonists Dolasetron Anzemet 50 mg tablet PA; SP Reserved for treatment failure of (Anzemet) Anzemet 100 mg tablet PA; SP Ondansetron and Granisetron Tablets Reserved for members with documented Granisetron 3.1 mg/24 hr PA; SP inability to take medications by mouth, transdermal patch (Sancuso Granisetron (Kytril, including ODT formulations. Sancuso) Reserved for patients with documented Granisetron Tablets (Kytril) PA treatment failure of dose optimized Ondansetron therapy Ondansetron 4 mg disintegrating QL tablet Ondansetron 8 mg disintegrating QL Limit 60 tablets per 30 days. tablet Ondansetron Ondansetron Hcl 4 mg tablet QL (Zofran) Ondansetron Hcl 8 mg tablet QL Ondansetron 4 mg/5 ml solution NF Ondansetron 40 mg/20 ml vial NF Ondansetron HCL 4 mg/2 ml vial NF Reserved for use in patients receiving Palonosetron Aloxi 0.25 mg/5 ml intravenous highly-emetogenic chemotherapy, with PA; SP (Aloxi) solution treatment failure of ondansetron, or documented inability to swallow.
    [Show full text]